This virtual event launched the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections. 

Visit www.AMRActionFund.com to learn more.

Speakers (in order of appearance):

• David Ricks, Chairman and CEO, Eli Lilly and Company
• Michelle McMurry-Heath, President and CEO, BIO
• Brandon Noble, former NFL player
• Stephen J. Ubl, President and CEO, PhRMA
• Ken Frazier, Chairman and CEO, Merck
• Albert Bourla, Chairman and CEO, Pfizer
• Priscilla VanderVeer, Vice President, PhRMA
• ADM Brett P. Giroir, MD, Assistant Secretary for Health
• Senator Bob Casey (D-PA)
• Senator Bill Cassidy, MD (R-LA)
• Scott Gottlieb, resident fellow, American Enterprise Institute – moderator
• Helen Boucher, MD, board member and treasurer, Infectious Disease Society of America
• Kathy Talkington, director, Health Programs, The Pew Charitable Trusts
• Kevin Outterson, executive director and principal investigator, CARB-X
• Ramani Varanasi, founder/president/CEO, X-Biotix
• Michael Boyle, MD, president and CEO, Cystic Fibrosis Foundation